Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a --analysis

翻译者：刘宁宁   校对者：马丹   审阅者：张莉芸

Abstract -ive:Using --analysis methods, this study aimed to estimate the impact of biologic agents on physical function in patients with RA.Methods:A systematic literature search was conducted independently by two investigators. Double-blind randomized controlled trials (RCTs) investigating the efficacy of abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab or rituximab in approved dosages in comparison with treatment with non-biologic disease-modifying anti-rheumatic drugs (nbDMARDs) and placebo were included. The outcome parameter was improvement in function measured by the standardized mean difference (SMD) of HAQ scores. Conclusion:Treatment with biologics led to a clinically relevant greater improvement in physical function than treatment with nbDMARDs.

摘要 目的：使用荟萃分析方法评估生物制剂对类风湿关节炎患者躯体功能的影响。方法：两名调查员独立进行文献检索。包括用双盲，随机对照试验（RCT）调查：阿巴西普，阿达木单抗，妥珠单抗，依那西普，戈利木单抗，英夫利昔单抗或利妥昔单抗在推荐剂量内的有效性，以及与非生物改善病情抗风湿药物（nbDMARDs）或安慰剂疗效的对比。通过健康问卷评分的标准方差来评定患者的功能是否改善。结论：用生物制剂治疗RA比非生物改善病情抗风湿药在临床上能更好的改善患者的躯体功能。